The Substrate Series · Scale · 7 of 7

Why precision medicine depends on governed handoffs.

How institutions can exchange reviewable outputs without surrendering control.

← All perspectives
The Substrate Series · 7 of 7

A clinical trial may involve a sponsor, a CRO, multiple clinical sites, laboratories, and regulatory reviewers. Each one has its own systems, validation processes, and compliance requirements.

No single organization can reconcile all of that alone.

Precision medicine is already multi-institutional. Assays, studies, therapy evidence, and review records cross organizational boundaries.

A multi-site study may combine sequencing results, imaging, safety records, and study data from systems controlled by different organizations. The study team still needs a coherent, reviewable record of what crossed each boundary and how it was used.

· · ·

Composable outputs

The field scales when organizations can inspect and trust the evidence that crosses their boundaries.

That's not collaboration for its own sake. It's recognition that precision medicine is a system, and systems only work when the parts compose.

A governed layer does not require every organization to replace its systems or adopt one workflow. It carries identity context, provenance, applied rules, and review status across configured handoffs while each institution retains control of its infrastructure.

Veridata is designed to carry reviewable outputs across configured handoffs while each institution retains control of its systems and records.

← Previous: Evidence as a workflow output